Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Patients will receive either standard biological therapy (adalimumab) or experimental biological therapy with an IL-1 proinflammatory molecule blocker.
Main Inclusion Criteria: Patients aged 18 and older with an official diagnosis of ulcerative colitis who, with at least one previous line of treatment (either conventional or biological therapy), have symptoms of active disease. Previous biological therapy must not include only adalimumab; all other drugs are allowed.
Status: Soon enrolling patients
Start of patient enrollment: August 2024.
